<DOC>
	<DOC>NCT03092180</DOC>
	<brief_summary>As a T2T, our patients with idiopathic inflammatory myopathies will receive pulse therapies with methyprednisolone and/or human intravenous immunoglobulin, or only methyprednisolone at disease onset. This scheme is an internal routine protocol of our Service.</brief_summary>
	<brief_title>Optimizing Treatment on Idiopathic Inflammatory Myopathies</brief_title>
	<detailed_description>To compare two groups of patients as described in Brief Summary.</detailed_description>
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Myositis</mesh_term>
	<mesh_term>Immunoglobulins, Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho(D) Immune Globulin</mesh_term>
	<criteria>Idiopathic inflammatory myopathies Inclusion body myositis, muscular dystrophies, neoplasiaassociated myopathies, overlapped myopathies, others myopathies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Dermatomyositis</keyword>
	<keyword>Immunomodulation</keyword>
	<keyword>Immunosuppressive agents</keyword>
	<keyword>Myositis</keyword>
	<keyword>Polymyositis</keyword>
	<keyword>Necrotizing myopathies</keyword>
	<keyword>Antisynthetase syndrome</keyword>
</DOC>